https://www.selleckchem.com/pr....oducts/Rapamycin.htm
suggesting ruxolitinib as a promising treatment option in SR-cGVHD. In this small, single-site case series, ruxolitinib demonstrated a significant response in heavily pretreated patients with SR-cGVHD and a reasonably well-tolerated safety profile. The results add to the body of literature suggesting ruxolitinib as a promising treatment option in SR-cGVHD. Acute respiratory distress syndrome (ARDS) confers high mortality risk among critically ill patients. Identification of biomarkers associated with ARDS risk may guide clinical diagn
Curtir
Comentario
Compartilhar
